loader from loading.io

Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni Kura Oncology

Empowered Patient Podcast

Release Date: 06/25/2024

Innovations in Cell Therapy for Relapsed and Refractory Multiple Myeloma with Dr. Chris Heery Arcellx TRANSCRIPT show art Innovations in Cell Therapy for Relapsed and Refractory Multiple Myeloma with Dr. Chris Heery Arcellx TRANSCRIPT

Empowered Patient Podcast

Dr. Chris Heery is Chief Medical Officer at Arcellx, a company focusing on developing anito-cel, a significant advancement in CAR-T cell therapy, to treat relapsed and refractory multiple myeloma (rrMM). Multiple myeloma is a rare type of blood cancer that affects plasma cells in the bone marrow and has few treatment options. Arcellx is showing promising data from clinical trials with patients with rrMM who have failed prior therapies and have received Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations from the FDA for anito-cel. Chris explains, "The company was...

info_outline
Innovations in Cell Therapy for Relapsed and Refractory Multiple Myeloma with Dr. Chris Heery Arcellx show art Innovations in Cell Therapy for Relapsed and Refractory Multiple Myeloma with Dr. Chris Heery Arcellx

Empowered Patient Podcast

Dr. Chris Heery is Chief Medical Officer at Arcellx, a company focusing on developing anito-cel, a significant advancement in CAR-T cell therapy, to treat relapsed and refractory multiple myeloma (rrMM). Multiple myeloma is a rare type of blood cancer that affects plasma cells in the bone marrow and has few treatment options. Arcellx is showing promising data from clinical trials with patients with rrMM who have failed prior therapies and have received Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations from the FDA for anito-cel. Chris explains, "The company was...

info_outline
Hyperbaric Oxygen Therapy for Treating PTSD and Cognitive Decline with Dr. Mohammed Elamir Aviv Clinics TRANSCRIPT show art Hyperbaric Oxygen Therapy for Treating PTSD and Cognitive Decline with Dr. Mohammed Elamir Aviv Clinics TRANSCRIPT

Empowered Patient Podcast

Dr. Mohammed Elamir, lead physician at Aviv Clinics, offers diagnostics and treatments for brain injuries such as PTSD, stroke, and traumatic brain injury and to address cognitive decline. After comprehensive physical and mental assessment, including brain scans, patients receive hyperbaric oxygen therapy and other therapies like psychotherapy and neurocognitive training. Individualized plans are designed to get to the root causes of neurological and cognitive issues and stimulate the growth of new cells and blood flow, even for patients with long-standing conditions.   Dr. Mo explains,...

info_outline
Hyperbaric Oxygen Therapy for Treating PTSD and Cognitive Decline with Dr. Mohammed Elamir Aviv Clinics show art Hyperbaric Oxygen Therapy for Treating PTSD and Cognitive Decline with Dr. Mohammed Elamir Aviv Clinics

Empowered Patient Podcast

Dr. Mohammed Elamir, lead physician at Aviv Clinics, offers diagnostics and treatments for brain injuries such as PTSD, stroke, and traumatic brain injury and to address cognitive decline. After comprehensive physical and mental assessment, including brain scans, patients receive hyperbaric oxygen therapy and other therapies like psychotherapy and neurocognitive training. Individualized plans are designed to get to the root causes of neurological and cognitive issues and stimulate the growth of new cells and blood flow, even for patients with long-standing conditions.   Dr. Mo explains,...

info_outline
Power of Gait Analysis to Predict and Monitor Health Conditions with Tomer Shussman OneStep TRANSCRIPT show art Power of Gait Analysis to Predict and Monitor Health Conditions with Tomer Shussman OneStep TRANSCRIPT

Empowered Patient Podcast

Tomer Shussman, the Co-Founder and CEO of OneStep, is at the forefront of motion intelligence and gait analysis. OneStep provides a smartphone app that monitors movement and provides real-time data about gait patterns and changes over time. The system can predict and prevent conditions like falls, provide information about overall health, and reveal early warning signs for Parkinson's, Alzheimer's, and other aging-related diseases. Integrating OneStep's gait analysis data with Epic electronic health records allows healthcare providers to streamline documentation and leverage gait data to...

info_outline
Power of Gait Analysis to Predict and Monitor Health Conditions with Tomer Shussman OneStep show art Power of Gait Analysis to Predict and Monitor Health Conditions with Tomer Shussman OneStep

Empowered Patient Podcast

Tomer Shussman, the Co-Founder and CEO of OneStep, is at the forefront of motion intelligence and gait analysis. OneStep provides a smartphone app that monitors movement and provides real-time data about gait patterns and changes over time. The system can predict and prevent conditions like falls, provide information about overall health, and reveal early warning signs for Parkinson's, Alzheimer's, and other aging-related diseases. Integrating OneStep's gait analysis data with Epic electronic health records allows healthcare providers to streamline documentation and leverage gait data to...

info_outline
Addressing Extracellular Matrix Breakdown That Leads to Age-Related Diseases with Dr. Sherif Idriss Elastin Biosciences TRANSCRIPT show art Addressing Extracellular Matrix Breakdown That Leads to Age-Related Diseases with Dr. Sherif Idriss Elastin Biosciences TRANSCRIPT

Empowered Patient Podcast

Dr. Sherif Idriss is the CEO of Elastin Biosciences, a company focused on targeting aging-related diseases by restoring elastin, a key protein in the extracellular matrix that provides elasticity and resilience to organs and tissues. They are developing small molecule therapies for diseases linked to elastin deficiency, including Williams syndrome and abdominal aortic aneurysm. As elastin degrades over time due to aging, it leads to loss of tissue structural integrity and function, contributing to numerous age-related diseases.   Sherif explains, "One of the hallmarks of aging is...

info_outline
Addressing Extracellular Matrix Breakdown That Leads to Age-Related Diseases with Dr. Sherif Idriss Elastin Biosciences show art Addressing Extracellular Matrix Breakdown That Leads to Age-Related Diseases with Dr. Sherif Idriss Elastin Biosciences

Empowered Patient Podcast

Dr. Sherif Idriss is the CEO of Elastin Biosciences, a company focused on targeting aging-related diseases by restoring elastin, a key protein in the extracellular matrix that provides elasticity and resilience to organs and tissues. They are developing small molecule therapies for diseases linked to elastin deficiency, including Williams syndrome and abdominal aortic aneurysm. As elastin degrades over time due to aging, it leads to loss of tissue structural integrity and function, contributing to numerous age-related diseases.   Sherif explains, "One of the hallmarks of aging is...

info_outline
Treating Septic Shock with Nanoparticle Formulation that Redistributes Nitric Oxide with Dr. Harven DeShield Vivacelle Bio TRANSCRIPT show art Treating Septic Shock with Nanoparticle Formulation that Redistributes Nitric Oxide with Dr. Harven DeShield Vivacelle Bio TRANSCRIPT

Empowered Patient Podcast

Dr. Harven DeShield is the CEO and Co-Founder of Vivacelle Bio, which is developing a nanoparticle-based treatment called VBI-S to address the underlying causes of septic shock. The treatment works by efficiently redistributing nitric oxide to help regulate blood pressure and improve organ function, reducing the need for traditional vasopressor treatments. Vivacelle is also developing a product to help address hemorrhagic shock and minimize reperfusion injury. Harven explains, "There are seven aspects to septic shock - actually eight. So, first, you have an infection. You have to have an...

info_outline
Treating Septic Shock with Nanoparticle Formulation that Redistributes Nitric Oxide with Dr. Harven DeShield Vivacelle Bio show art Treating Septic Shock with Nanoparticle Formulation that Redistributes Nitric Oxide with Dr. Harven DeShield Vivacelle Bio

Empowered Patient Podcast

Dr. Harven DeShield is the CEO and Co-Founder of Vivacelle Bio, which is developing a nanoparticle-based treatment called VBI-S to address the underlying causes of septic shock. The treatment works by efficiently redistributing nitric oxide to help regulate blood pressure and improve organ function, reducing the need for traditional vasopressor treatments. Vivacelle is also developing a product to help address hemorrhagic shock and minimize reperfusion injury. Harven explains, "There are seven aspects to septic shock - actually eight. So, first, you have an infection. You have to have an...

info_outline
 
More Episodes

Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. They also discovered other subtypes that were responsive, expanding the potential patient population. Understanding the role of menin and menin inhibitors in addressing abnormal gene expression and promoting healthy cell development opens the door to potential combination therapy, where menin inhibitors could be layered onto existing treatments for various cancers related to menin independence.

Mollie explains, "In oncology, we have gotten good at treating the end state, but cancer has many, many causes with a common final endpoint to the way the cells look. So, it's many, many different diseases all at once. We've learned and are learning that with better technology and a better understanding of cancer in general we can identify not just how to stop the end state but how to stop it from starting."

"That's where ziftomenib comes in. Ziftomenib addresses key mutations that when they occur, are what cause the development of cancer. So you're able to shut down the development and force the cells to develop normally rather than waiting until they're already diseased and killing them with chemotherapy or some other cytotoxic agent."

"There is a protein complex that we refer to as the menin MLL complex, which goes rogue when something unusual happens in the cell. For example, that could be an NPM1 mutation. That could be a KMT2A rearrangement. Those are two things that are well-known to happen within AML diseases. It could also be a SETD2 RUNX1 mutation. So many types of mutations could happen that could cause this machinery to go rogue within the cell. And that complex causes genes to become active at levels and at times that are abnormal."

#KuraOncology #Ziftomenib #MeninInhibitors #PrecisionMedicine #BTD #AML

KuraOncology.com

Download the transcript here

Kura Oncology